Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

hiPSCs in cardio-oncology: deciphering the genomics

22 Jan 2019

Abstract excerpt

The genomic predisposition to oncology-drug-induced cardiovascular toxicity has been postulated for many decades. Only recently has it become possible to experimentally validate this hypothesis via the use of patient-specific human-induced pluripotent stem cells (hiPSCs) and suitably powered genome-wide association studies (GWAS). Identifying the individual single nucleotide polymorphisms (SNPs) responsible for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Pluripotent Stem Cells Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30689737
DOI: 10.1093/cvr/cvz018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

hiPSCs in cardio-oncology: deciphering the genomicsPMID 30689737Read ↗

Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity.Semantic proximity Read ↗

Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.Semantic proximity Read ↗

Personalized medicine in cardio-oncology: the role of induced pluripotent stem cellSemantic proximity Read ↗

Understanding the Mechanisms of Chemotherapy-Related Cardiotoxicity Employing hiPSC-Derived Cardiomyocyte Models for Drug Screening and the Identification of Genetic and Epigenetic VariantsSemantic proximity Read ↗

Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?Semantic proximity Read ↗

Genetic Background in Patients with Cancer Therapy-Induced CardiomyopathySemantic proximity Read ↗

Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk.Semantic proximity Read ↗

Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.Semantic proximity Read ↗

Novel stem cell-based drug discovery platforms for cardiovascular disease.Semantic proximity Read ↗

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity.Semantic proximity Read ↗

Harnessing human genetics and stem cells for precision cardiovascular medicineSemantic proximity Read ↗

Editing the genome of hiPSC with CRISPR/Cas9: disease models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.